Pfizer Inc. is entering 2023 with a full head of steam after announcing three applications for US FDA approval during the typically busy year-end period.
Keeping Track: A Blizzard Of Submissions At The US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
